FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This...

Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $...

Sanofi's phase 3 GMMG-HD7 study reveals that Sarclisa, combined with lenalidomide, bortezomib, and dexamethasone, significa...

Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD...

Argus Research analyst Jasper Hellweg maintains Sanofi (NASDAQ:SNY) with a Buy and raises the price target from $55 to $60.

Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last q...

Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a...

Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead t...

Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment T...